Canada: Federal Court Prohibits Issuance Of NOC To Teva For Atazanavir Sulfate, Prior Genus Patent Does Not Anticipate Compound Claim

Last Updated: August 2 2016
Article by Kevin Siu

On June 8, 2016, the Federal Court issued an order under the Patented Medicines (Notice of Compliance) Regulations prohibiting the Minister of Health from issuing a notice of compliance to Teva for atazanavir sulfate (Bristol-Myers Squibb's (BMS) REYATAZ) until expiry of Novartis AG's Patent No. 2,250,840 ("840 patent"): Bristol-Myers Squibb Canada Co v Teva Canada Limited, 2016 FC 580. The Court dismissed the prohibition application relating to BMS's Patent No. 2,317,736 ("736 patent").

840 Patent – allegations of invalidity were not justified

The 840 is a compound patent, claiming atazanavir.

Admissibility of prior art

A preliminary dispute arose regarding admissible prior art. Teva asserted that Australian Patent Application 9352479 (AU '479), which was filed and published before the relevant date, disclosed a compound which would have been the "starting point" in an obviousness analysis. However, on the face of the specification, the impugned pages were stamped with an August 12, 1996 date, which was after the relevant date in this case. Neither party provided evidence from an Australian patent law expert, but the Court drew the "logical inference" that the pages were added after filing. The specific claim on those pages disclosing a relevant compound therefore did not form part of the prior art.

Teva also relied on a letter from the patentee to the European Patent Office which allegedly disclosed some testing data on the effectiveness of the prior art compound. The Court found that there was no evidence to establish the letter was available to the public at the relevant date. The Court also rejected the letter as prior art on the basis that it was in German and no English translation was provided, and because Teva did not cite the letter as prior art in its notice of allegation and was thus not entitled to rely on it.


Inventive concept – in the first stage of the obviousness analysis, the Court construed the inventive concept to be "a particular protease inhibitor (atazanavir) that is useful in the inhibition of HIV infections, and which has four advantageous properties": high degree of cellular activity better than saquinavir, indinavir, and ritonavir; high oral bioavailability/blood levels/plasma concentrations; advantageous resistance profile; and high selectivity against HIV protease.

The Court also commented on the expert evidence regarding inventive concept. Since Teva's expert witness did not describe in his affidavit the instructions he had received on how to identify the inventive concept and could not recall those instructions on cross-examination, instead providing a "faulty understanding of the requirements of Canadian patent law", the evidence of BMS's expert was preferred by the Court.

Starting point – the Court rejected that a specific compound asserted by Teva to be claimed in the AU '479 application was the appropriate starting point, based on the above factual findings. Moreover, the inventors' course of conduct supported the argument that the asserted example was not the obvious starting point, as they tried many other approaches. However, the Court accepted that the azapeptide "backbone" was "one, but by no means the only, logical place to start".

Obvious to try – Teva argued that the inventors' modifications to the starting backbone were obvious to try. The Court rejected the submissions that the substitutions the inventors made were obvious to try, as they were not "more or less self evident" to the skilled person. In particular, it was not possible for the skilled person to predict the impact of structural changes on pharmaceutical properties and bioavailability.


A threshold issue arose as to whether atazanavir fell within the scope of a prior art genus patent. The Court held that it did not, preferring BMS's expert evidence on the meaning of "arylalkyl". This was dispositive of the issue and the Court held Teva's anticipation allegations to be unjustified.

However, the Court went on to consider the allegations of anticipation on the merits, and found that the asserted genus patent did not anticipate the compound. On the disclosure requirement, the Court found that the genus patent did not disclose advantageous properties of atazanavir, which were part of the construed inventive concept. On the enablement requirement, the Court found that there was "no clear direction to get to atazanavir" from the prior art, therefore no enablement for the claimed compound. Thus, Teva's anticipation allegations were also unjustified for those reasons.

736 Patent – allegations of invalidity were justified

The 736 patent claims the bisulphate salt of atazanavir.

Claim construction

The primary point of contention between the parties was whether the claim to "a bisulphate salt of" atazanavir and a dependent claim included both Type-I and Type-II polymorphic forms of atazanavir bisulphate (as asserted by Teva), or only Type-I (as asserted by BMS). After reviewing extensive expert evidence on construction and the patent specification, the Court concluded that the claim, which provided a specific chemical structure for the Type-I form, encompassed only Type-I.


The Court found that the work in making the bisulphate salt was part of a "standard salt screen", and that it was arrived at without difficulty—in this case on the "first day" of the drug development project. With respect to characterization of the salts and their properties such as solubility, stability, and hygroscopicity, the Court did not consider the work to have been either prolonged or arduous. Thus, the Court concluded that Teva's allegations of obviousness were justified. Bristol-Myers Squibb has appealed.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Kevin Siu
In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.